-+ 0.00%
-+ 0.00%
-+ 0.00%

ELIQUENT Life Sciences Joins €13 Million Horizon Europe Consortium to Advance Regulatory Development of Novel Osteoarthritis Therapy

Barchart·10/29/2026 06:00:00
Listen to the news

ELIQUENT will contribute regulatory development expertise to ExoCordOA, a five-year European program advancing secretome-based therapeutics toward clinical use

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.